Clinical Efficacy of Modified Bixie Shengshitang on Acute Gouty Arthritis Due to Hot and Humid Syndrome
10.13422/j.cnki.syfjx.20201984
- VernacularTitle:加味萆薢胜湿汤治疗急性痛风性关节炎湿热痹阻证的临床观察
- Author:
Zhong-bo ZHANG
1
;
Dong-liang SHI
1
;
Xu-zhao DU
2
;
Shao-xiang YANG
2
Author Information
1. Henan University of Chinese Medicine， Zhengzhou 450046， China
2. The Second Affiliated Hospital of Henan University of Chinese Medicine， Zhengzhou 450002， China
- Publication Type:Research Article
- Keywords:
modified Bixie Shengshitang;
colchicine;
acute gouty arthritis;
hot and humid syndrome
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(22):65-70
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of modified Bixie Shengshitang on acute gouty arthritis due to hot and humid syndrome. Method:According to the random number table method， 130 cases were randomly divided into control group and observation group， with 65 cases in each group. All of the cases were given the basic non-drug therapy. The control group was given colchicine， while observation group was given modified Bixie Shengshitang + colchicine for 14 d. Before treatment and at 3， 7 and 14 d after treatment， total symptom score （TSS） and traditional Chinese medicine （TCM） syndrome were observed between the two groups， respectively. Blood uric acid （BUA）， urinary uric acid （UUA）， erythrocyte sedimentation rate （ESR）， proinflammatory factors ［tumor necrosis factor-α （TNF-α）， interleukin-1 （IL-1）， interleukin-8 （IL-8）］ and anti-inflammatory factors ［interforon gamma receptor （IFN-γ）， interleukin-4 （IL-4）， interleukin-18（IL-18）］ in serum and joint fluid were detected before and after treatment. The clinical efficacy and safety of the two groups were compared. Result:The total effective rate was 96.9% （62/64） in observation group， which was higher than 80.6% （50/62） in control group （χ2=5.713， P<0.05）. Compared with control group at 3， 7 and 14 d after treatment， TSS and TCM syndrome scores in observation group were significantly reduced （P<0.05）. Compared with control group after treatment， BUA， ESR， TNF-α， IL-1β， IL-8 and UUA， IFN-γ， IL-4 and IL-18 were significantly decreased in observation group （P<0.05）. There was no serious adverse event during the study period. The incidence of adverse reactions was 54.7% （35/64） in observation group， which was lower than 82.3% （51/62） in control group （χ2=9.326， P<0.05）. Conclusion:Modified Bixie Shengshitang can significantly alleviate the clinical symptoms of patients with acute gouty arthritis due to hot and humid syndrome， and adjust levels of uric acid and inflammatory cytokines， with a low recurrence rate.
